Now Approved: U.S. FDA approves product to reduce the incidence of catheter-related bloodstream infections (CRBSIs) under special pathway for patients receiving hemodialysis.

Press releases

Here you can find corporate releases on topics related to governance, investments, and important announcements.

Read more

Investors

Nasdaq:

CRMD

$ 3.55 Last update: 12/07/2023 5:49:47 am ET Time Read more

About CRBSI

Learn more about Catheter-related blood stream infections (CRBSIs) and how they affect hemodialysis central venous catheter (HD-CVC) patients.

Read more
WHY CORMEDIX

We relentlessly pursue therapeutic options to reduce and treat infectious and inflammatory disease

About us